Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | FCER2 | P06734 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | MASP2 | O00187 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431835 | 1.00 | CPB2 (0.43) | CPB2MMP1FCER2KLKB1F2R | |
| SCHEMBL15901636 | 0.86 | KLKB1 (0.56) | CPB2MMP1FCER2KLKB1F2R | |
| SCHEMBL14485428 | 0.86 | KLKB1 (0.56) | CPB2MMP1FCER2KLKB1F2R | |
| SCHEMBL3155821 | 0.85 | F2 (0.55) | F2RMASP2F2 | |
| SCHEMBL3155827 | 0.85 | F2 (0.55) | F2RMASP2F2 | |
| SCHEMBL3149376 | 0.84 | MASP2 (0.43) | KLKB1KLK1MASP2EPHX2 | |
| SCHEMBL1431486 | 0.84 | MASP2 (0.43) | KLKB1KLK1MASP2EPHX2 | |
| SCHEMBL3154833 | 0.84 | MASP2 (0.48) | CPB2MASP2METAP2METAP1F2 | |
| SCHEMBL1431700 | 0.84 | KLKB1 (0.49) | MMP1FCER2KLKB1KLK1MASP2 | |
| SCHEMBL3153048 | 0.84 | KLKB1 (0.49) | MMP1FCER2KLKB1KLK1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CPB2 2005/4885MMP1 2614/4885FCER2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.